Ocugen Signs Exclusive Licensing Deal for OCU400 Gene Therapy in MENA Region

Key Facts

1Ocugen executed an exclusive licensing agreement with Roots Pharmaceutical and its partner Al-Dhow International Holding.

2The agreement grants exclusive rights for OCU400, a gene therapy for Retinitis Pigmentosa, in the MENA region.

Ocugen executed an exclusive licensing agreement with Roots Pharmaceutical and its partner Al-Dhow International Holding for the rights to OCU400 in the Middle East and North Africa. GlobeNewswire reported that the deal grants exclusive rights for the modifier gene therapy, which targets Retinitis Pigmentosa, as part of the company's strategy to expand its clinical-stage pipeline globally.

OCGN closed at $0.8854 on October 13, 2026, after trading between a session low of $0.87 and a high of $0.9454. The partnership intends to utilize the regional expertise of Roots Pharmaceutical, a Kuwait-based healthcare provider, to commercialize Ocugen's blindness disease therapies across the MENA region.